editorial

It’s that time again. Friday’s the chance to review the week just gone. This week it’s been Heart Rhythm 2012, so there’s plenty to chew on as the controversies and indeed the advances keep coming.

You say potato, I say prosthesis. While somehow a therapeutic cranberry capsule has uniquely found its way to market as a medical device, we’re scratching our heads about the whole affair.

We can’t even harmonise the spelling of the word harmonize, so what chance of bringing our regulatory processes closer together?

US regulatory agency the FDA issues very public warning letters to companies which are then trotted out around the media so we can all revel in the organisations pain. But would this level of openness be well received in Europe where medical device regulations seem to be in the media’s crosshairs too frequently for the industry’s own good.

We get really really fed up with medical device companies trotting out lightweight press releases about newly CE marked products, like we’re all going to say “great” and rush out to use them. This is a plea to companies to provide their evidence and let us decide whether it passes muster.

Medlatest seeks to be end-user focused and international. We’re asking you if we’re hitting the spot.